Glenmark 
Welcome,         Profile    Billing    Logout  
 23 Products   47 Diseases  23 Products   158 Trials   2211 News 
187 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ISC 17536 / Glenmark
2013-002728-17: A 4 week study to evaluate efficacy, safety and tolerability of Inhaled GRC 17536 in Patients with Refractory Chronic Cough

Ongoing
2
48
Europe
GRC 17536 potassium powder for inhalation, GRC 17536 potassium,
Glenmark Pharmaceuticals SA, Glenmark Pharmaceuticals SA
Refractory Chronic Cough.
 
 
telazorlimab (ISB 830) / Astria Therap
2018-000783-29: A Study of GBR 830 in Adult Patients with Atopic Dermatitis

Not yet recruiting
2
468
Europe
ISB 830, Powder for solution for infusion
Ichnos Sciences SA, Inchos Sciences SA (renamed from Glenmark Pharmaceuticals SA), Ichnos Sciences SA, Inchos Sciences SA
Moderate to severe atopic dermatitis, Moderate to severe eczema, Diseases [C] - Immune System Diseases [C20]
 
 
Cibinqo (abrocitinib) / Pfizer
NCT05602207: Effects of Abrocitinib in Subjects With Atopic Dermatitis With an Unsatisfactory Response After Treatment With Dupilumab

Completed
4
24
Canada, US
Abrocitinib, CIBINQO
Innovaderm Research Inc.
Atopic Dermatitis
12/24
01/25
DermAtOmics-II, NCT06366932: Optimization of Atopic Dermatitis Treatment That Requires Second-line Systemic Therapy Through Predictive Models

Recruiting
4
150
Europe
Second-line systemic treatment, Dupilumab, Tralokinumab, Upadacitinib, Baricitinib, Abrocitinib, Folllow-up of second-line systemic treatment already started
Instituto de Investigación Hospital Universitario La Paz
Atopic Dermatitis
09/25
09/25
ChiCTR2400086045: Registry of Chinese atopic dermatitis (AD) patients receiving abrocitinib

Recruiting
4
2000
 
None
The First Hospital of China Medical University; The First Hospital of China Medical University, China Primary Health Care Foundation
Atopic dermatitis (AD)
 
 
NCT05375929 / 2024-000141-26: A Study to Learn About Abrocitinib Tablets in People With Atopic Dermatitis in India

Completed
3
200
RoW
Abrocitinib 100 mg, Abrocitinib 200 mg
Pfizer, Pfizer Inc.
Atopic Dermatitis
06/23
03/24
2024-000141-26: The purpose of this clinical trial is to learn about the safety and how well the study medicine (called Abrocitinib) works for the potential treatment of moderate to severe Atopic Dermatitis (AD) in India.

Not yet recruiting
3
200
RoW
Abrocitinib, PF-04965842, Film-coated tablet, Cibinqo
Pfizer Inc., Pfizer Inc.
Moderate to severe atopic dermatitis, Atopic dermatitis is also known as atopic eczema. It is a type of inflammation of the skin that results in itchy, red, swollen, and cracked skin., Diseases [C] - Skin and Connective Tissue Diseases [C17]
 
 
NCT06807268: A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema

Not yet recruiting
3
150
Japan, US
Abrocitinib, PF-04965842, Placebo
Pfizer
Eczema
05/27
05/27
NCT06807281: A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema

Not yet recruiting
3
500
NA
Abrocitinib, PF-04965842
Pfizer
Atopic Dermatitis
02/32
02/32
JADE EXTEND, NCT03422822 / 2017-004851-22: Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

Hourglass Jul 2021 - Sep 2021 : From JADE EXTEND trial for patients 12 years and older with atopic dermatitis
Active, not recruiting
3
3164
Europe, Canada, Japan, US, RoW
Abrocitinib 100 mg, Abrocitinib 200 mg, Placebo
Pfizer
Dermatitis, Atopic
12/25
12/25
NCT05696795: Janus Kinase Inhibition in Sarcoidosis

Completed
2
10
US
Abrocitinib 200 mg
Yale University, Pfizer
Sarcoidosis
04/25
04/25
NCT06283550: Efficacy, Safety, and Tolerability of Abrocitinib in Subjects With Moderate to Severe Chronic Hand Eczema Refractory to Corticosteroid Therapy

Active, not recruiting
2
84
Canada
Abrocitinib 200 mg, CIBINQO, Abrocitinib 100 mg, Placebo, Inert tablet
Innovaderm Research Inc.
Chronic Hand Eczema
11/25
12/25
NCT05650736: Janus Kinase Inhibition in Granuloma Annulare

Active, not recruiting
2
10
US
Abrocitinib 200 mg
William Damsky, Yale University, Pfizer
Granuloma Annulare
05/24
07/25
CLEAR-LC, NCT06597396: Study to Investigate the Efficacy of Abrocitinib in Adult Participants with Severe Fatigue from Post COVID Condition/Long COVID

Recruiting
2
90
US
Abrocitinib, Placebo
Beth Israel Deaconess Medical Center, Pfizer
Post-COVID Condition, Fatigue Symptom
01/26
06/26
NCT05743244: Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D)

Recruiting
2
78
Canada, US, RoW
Abrocitinib 200 MG Oral Tablet, CIBINQO, Ritlecitinib, Placebo
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Pfizer
Diabetes Mellitus, Type 1
06/26
06/27
NCT05069831: JAK Inhibition in Food Allergy

Completed
1
71
US
Abrocitinib
Icahn School of Medicine at Mount Sinai
Food Allergy
06/25
06/25
TEN, NCT06119490: Evaluation of the Efficacy and Safety of Methylprednisolone Combined With the JAK Inhibitors in the Treatment of Toxic Epidermal Necrolysis

Recruiting
1
30
RoW
Abrocitinib, Solu-Medrol®, Tofacitinib
Peng Zhang
Toxic Epidermal Necrolysis
07/26
09/26
NCT04564755 / 2020-003610-12: Abrocitinib Expanded Access Protocol in Adolescents and Adults With Moderate to Severe Atopic Dermatitis

No Longer Available
N/A
Europe, Canada, US, RoW
abrocitinib
Pfizer
Atopic Dermatitis
 
 
NCT05466578: Pre-approval Single-patient Expanded Access for Abrocitinib (PF-04965842)

Available
N/A
NA
abrocitinib
Pfizer, In Expanded Access, treating physicians are the Sponsor
Severe Uncontrolled Atopic Dermatitis
 
 
AbroSkib, NCT05140239: Effects of Abrocitinib Treatment on Skin Barrier Function

Active, not recruiting
N/A
20
Europe
No Intervention
Prof. Dr. Stephan Weidinger
Atopic Dermatitis
09/24
06/25
ATTRACT, NCT06353087: Abrocitinib Taiwan Treatment Pattern and Real World Study in ATopiC Dermatitis ( Registry)

Recruiting
N/A
200
RoW
Pfizer
Dermatitis, Atopic, Dermatitis, Eczema, Skin Diseases, Immune System Diseases, Janus Kinase Inhibitors
05/26
05/26
RWE, NCT06573593: Efficacy and Safety of JAK Inhibitors in Patients With AA: Study

Recruiting
N/A
150
RoW
Tofacitinib, Baricitinib, Ruxolitinib, Upadacitinib, Abrocitinib, Ritlecitinib
Second Affiliated Hospital, School of Medicine, Zhejiang University
Alopecia Areata, Janus Kinase Inhibitors
12/26
12/26
ChiCTR2500097331: Study on the microscopic characteristics of skin blood vessels in inflammatory skin diseases and the efficacy and safety of abrocitinib tablets combined with Crisborole ointment in the treatment of moderate to severe atopic dermatitis

Completed
N/A
300
 
None; None; The patient takes 100mg of Abrocitinib once daily and applies Crisaborole ointment twice daily for a duration of three months.
China-Japan Friendship Hospital; The Beijing Qingnang Huimin Medical Research Institute Co., Ltd., Horizontal project
Atopic Dermatitis
 
 
NCT05250115: A Study to Learn About Abrocitinib in Adult Patients With Moderate to Severe Atopic Dermatitis

Terminated
N/A
112
Europe
Pfizer
Dermatitis, Atopic
07/24
07/24
ChiCTR2500098251: Abrocitinib in the Treatment of Glucocorticoid-Refractory Acute Urticaria: A Case Series

Recruiting
N/A
5
 
Zhejiang Provincial Tongde Hospital; Zhejiang Provincial Tongde Hospital, Self-funded
Acute urticaria
 
 
NCT06899204: Real World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate Response to Previous Biologic Therapies.

Not yet recruiting
N/A
150
NA
Abrocitinib, Cibinqo
Pfizer
Atopic Dermatitis, Atopic Dermatitis, Unspecified, Dermatitis, Atopic
07/26
08/26
ChiCTR2400090334: Efficacy and Safety of Abrocitinib and Upadacitinib in the Treatment of Children (Aged Below 12) with Moderate to Severe Atopic Dermatitis: A Real World Study

Recruiting
N/A
25
 
therapeutic agents: abrocitinib or upadacitinib
Guangzhou Dermatology Hospital; Guangzhou Dermatology Hospital, Project Fund
atopic dermatitis
 
 
ChiCTR2500097613: To analyze real-world data of abrocitinib in the treatment of adolescents with moderate-to-severe atopic dermatitis (AD) in Guangzhou, China

Recruiting
N/A
60
 
Guangzhou Dermatology Hospital; Guangzhou Dermatology Hospital, Self-funded
atopic dermatitis
 
 
ADAIR, NCT05689151: A Study to Learn About Abrocitinib in Adult Patients With Moderate to Severe Atopic Dermatitis.

Recruiting
N/A
183
Europe
Abrocitinib
Pfizer
Atopic Dermatitis, Eczema
06/26
05/27
ChiCTR2400089103: Exploration and Validation of the Targeted Treatment Protocol for Atopic Dermatitis in China

Not yet recruiting
N/A
200
 
Administer 100 mg of abrocitinib orally once daily to the patient.; Administer 200 mg of abrocitinib orally once daily to the patient.; Administer 300 mg of Dupixent by injection every two weeks to the patient.
Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College; Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Pfizer general research grant No.78229835
Atopic Dermatitis
 
 
NCT05387980: A Study to Learn About the Study Medicine (CIBINQO) in People With Atopic Dermatitis.

Recruiting
N/A
1200
Japan
CIBINQO
Pfizer
Atopic Dermatitis
08/28
08/28
NCT05391061: A Study to Learn About the Study Medicine (Called Cibinqo) in People With Atopic Dermatitis

Recruiting
N/A
1100
RoW
Abrocitinib, Cibinqo
Pfizer
Dermatitis, Atopic
11/27
11/27
NCT03358693: Molecular Signatures in Inflammatory Skin Disease

Recruiting
N/A
300
Europe
Ustekinumab, Infliximab, Secukinumab, Dupilumab, Brodalumab, Ixekizumab, Baricitinib, Abrocitinib, Upadacitinib, Tralokinumab
Prof. Dr. Stephan Weidinger
Atopic Dermatitis, Psoriasis
12/27
12/28
NCT05721937: A Study of How Safe Abrocitinib (CIBINQO) is in Pregnant Women and Their Offspring

Recruiting
N/A
400
US
Abrocitinib
Pfizer, PPD Development, LP
Atopic Dermatitis
12/27
12/27
Winlevi (clascoterone cream 1%) / Cosmo Pharma
NCT06415305: A Study Evaluating the Efficacy and Safety of Clascoterone Cream 1% in Skin of Color Patients With Acne

Completed
4
10
US
Winlevi (clascoterone) 1% cream
Sun Pharmaceutical Industries Limited
Acne Vulgaris
04/24
01/25
NCT06336629: A Study Assessing the Efficacy of Combined Use of Clascoterone 1% Cream and Duac Gel (Benzoyl Peroxide/Clindamycin) for the Treatment of Acne

Completed
4
10
US
Winlevi (clascoterone) 1% & Duac gel
Sun Pharmaceutical Industries Limited
Acne Vulgaris
07/24
07/24
NCT06336603: A Study Assessing the Efficacy of Combined Use of Clascoterone 1% Cream and Adapalene 0.3% for the Treatment of Acne

Completed
4
20
US
Winlevi (clascoterone) 1% & Adapalene 0.3% gel
Sun Pharmaceutical Industries Limited
Acne Vulgaris
10/24
10/24
NCT06415292: A Study to Evaluate the Impact of Clascoterone 1% Cream on Skin Barrier Properties in Acne Prone Patients

Completed
4
50
US
Winlevi (clascoterone) 1% cream
Sun Pharmaceutical Industries Limited
Acne Vulgaris
12/23
12/23
NCT06415279: A Study to Evaluate the Reduction in Sebum (Skin Oil) Induced by Clascoterone Cream 1% in Acne Patients

Completed
4
40
US
Winlevi (clascoterone) 1% cream
Sun Pharmaceutical Industries Limited
Acne Vulgaris
02/25
02/25
NCT06425900: A Study to Assess Sebaceous Gland Changes and Constituents of Sebum (Skin Oil) Induced by Clascoterone 1% Cream in Acne Patients

Active, not recruiting
4
10
US
Winlevi (Clascoterone) cream 1%
Sun Pharmaceutical Industries Limited
Acne Vulgaris
09/25
09/25
2023-000463-32: Study to Evaluate the Safety and Efficacy of CB-03-01 Cream, 1% in Subjects with Facial Acne Vulgaris

Not yet recruiting
3
708
US, RoW
cortexolone 17alpha-propionate, CB-03-01, Cream
CASSIOPEA SpA, CASSIOPEA SpA
Facial Acne Vulgaris, Facial Acne, Diseases [C] - Skin and Connective Tissue Diseases [C17]
 
 
NCT06403501: Efficacy and Safety of Clascoterone Cream 1% in Facial Acne Vulgaris

Recruiting
3
692
RoW
Clascoterone, Winlevi (brand name), Vehicle cream
Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd.
Acne Vulgaris
02/25
02/25
SCALP1, NCT05910450: A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss

Recruiting
3
726
US, RoW
Clascoterone 5% solution, CB-03-01 5% solution, Vehicle solution, Vehicle
Cassiopea SpA, Ergomed PLC, Pharmapace Inc, Canfield Scientific Inc., ICON Clinical Research
Alopecia, Androgenetic
10/24
04/25
SCALP2, NCT05914805: A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss

Recruiting
3
726
Europe, US
Clascoterone 5% solution, CB-03-01 5% solution, Vehicle solution, Vehicle
Cassiopea SpA, Ergomed PLC, Pharmapace Inc, Canfield Scientific Inc., ICON Clinical Research
Alopecia, Androgenetic
08/24
03/25
2023-000461-13: A Phase 2 Dose Escalating Study to Evaluate the Safety and Efficacy of CB-03-01 Cream in Subjects With Facial Acne Vulgaris

Not yet recruiting
2
363
US
cortexolone 17alpha-propionate, CB-03-01, Cream
Intrepid Therapeutics Inc., Cosmo SpA
Facial Acne Vulgaris, Facial Acne, Diseases [C] - Skin and Connective Tissue Diseases [C17]
 
 
NCT06286397: Topical Anti-Androgens in Pilonidal Sinus Disease

Not yet recruiting
2
75
US
1% Clascoterone, Vehicle Cream
University of Pennsylvania
Pilonidal Disease, Pilonidal Disease of Natal Cleft, Pilonidal Sinus, Pilonidal Cyst
08/27
12/27
NCT06952517: Efficacy and Safety of Topical Clascoterone (WINLEVI) Cream 1% in Patients With Facial Acneiform Rosacea

Recruiting
2
20
US
Clascoterone Cream 1%, WINLEVI
Narrows Institute for Biomedical Research, Sun Pharmaceutical Industries Limited
Papular-pustular Rosacea, Papulopustular Rosacea (PPR), Papulopustular Rosacea
09/25
09/25
NCT05891795: Clascoterone for Steroid-related Acne Vulgaris in Transgender Male Patients Receiving Masculinizing Hormone Therapy

Recruiting
1/2
18
US
Clascoterone 1% Top Cream, Vehicle
Stanford University
Acne Vulgaris
12/25
12/25
NCT06454708: Pharmacokinetics, Safety and Tolerability of Clascoterone Cream 1% in Healthy Chinese Adult Subjects

Completed
1
12
RoW
Clascoterone Cream 1%
Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd.
Acne Vulgaris
08/24
08/24
Akynzeo oral (netupitant/palonesteron FDC) / Helsinn
ACTRN12620000455965p: Akynzeo for post-operative nausea and vomiting after bariatric surgery.

Not yet recruiting
4
86
 
St Vincent's Hospital Melbourne, St Vincent's Hospital Melbourne Research Endowment Fund
morbid obesity; Post-operative nausea and vomitting
 
 
ACTRN12620000455965: Akynzeo for post-operative nausea and vomiting after bariatric surgery.

Recruiting
4
160
 
St Vincent's Hospital Melbourne, St Vincent's Hospital Melbourne Research Endowment Fund
morbid obesity, Post-operative nausea and vomitting
 
 
NOEME, NCT06726291: Akynzeo as Antiemetic Treatment in Patients With Endometrial Cancer

Recruiting
4
84
Europe
NEPA (300mg netupitant/0.5mg palonosetron)
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Endometrial Cancer
12/25
06/26
NCT04817189 / 2019-004686-41: Oral Akynzeo® Vs Standard of Care in Preventing CINV in High-risk MEC Patients (MyRisk)

Completed
4
414
Europe, RoW
NEPA (300mg netupitant/0.5mg palonosetron), Akynzeo® capsules, Granisetron, 2 mg (oral) or 1 mg (IV) OR Palonosetron, 0.5 mg (oral), 0.25mg (IV) OR Ondansetron, 16 mg (oral) or 8 mg (IV) OR Dolasetron 100 mg (oral) OR Tropisetron 5 mg (oral or IV), 5-HT3 RA, Dexamethasone, 8 mg (oral) or equivalent IV dose, corticosteroid
Helsinn Healthcare SA
Chemotherapy-induced Nausea and Vomiting
07/24
07/24
NCT06331520: NEPA Combined With Olanzapine, Dexamethasone-sparing for the Effect of CINV in Patients Receiving HEC Regimens

Not yet recruiting
3
627
NA
Netupitant / Palonosetron Oral Capsule [Akynzeo], Olanzapine, Dexamethasone Oral
Fudan University
Chemotherapy-induced Nausea and Vomiting, Highly Emetogenic Chemotherapy
05/25
05/26
NCT03367572: Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer

Completed
3
1351
US
Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Fluorodelta, Fortecortin, Gammacorten, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, Visumetazone, Laboratory Biomarker Analysis, Netupitant/Palonosetron Hydrochloride, Akynzeo, Olanzapine, LY 170053, Zydis, Zyprexa, Zyprexa Zydis, Placebo, placebo therapy, PLCB, sham therapy, Prochlorperazine, RP 6140, SKF-4657, Quality-of-Life Assessment, Quality of Life Assessment
University of Rochester NCORP Research Base, National Cancer Institute (NCI)
Breast Carcinoma
04/24
04/24
NCT03668639: Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin

Recruiting
2/3
80
Europe
Akynzeo, Dexamethasone
Christina Ruhlmann, Helsinn Healthcare SA
Chemotherapy-induced Nausea and Vomiting, Adverse Event, Cervical Cancer
03/23
04/23
2015-003318-26: Phase II, open-label, not comparative, multicenter study of multiple doses of NEPA (Netupitant+Palonosetron) in preventing chemotherapy induced nausea and vomiting(CINV) in patient with Non Hodgkin’s Lymphomareceiving salvage chemotherapy followed by high dose chemotherapy and autologous hematopoietic stem cells support. Studio di fase II, in aperto, non comparativo, multicentrico, di dosi ripetute di NEPA (netupitant + palonosetron) nella prevenzione della nausea ed il vomito indotti da chemioterapia (CINV) in pazienti con Linfoma Non-Hodgkin trattati con chemioterapia di salvataggio seguita da alte dosi di chemioterapia con supporto di cellule staminali ematopoietiche

Ongoing
2
81
Europe
AKYNZEO, EU/1/15/1001/001, Capsule, hard, AKYNZEO
ASSOCIAZIONE SALENTINA ANGELA SERRA ONLUS, ITALFARMACO S.P.A.
NON HODGKIN'S LYMPHOMA LINFOMA NON HODGKIN, NON HODGKIN'S LYMPHOMA LINFOMA NON HODGKIN, Diseases [C] - Cancer [C04]
 
 
2017-004031-37: A study to investigate the safety and antiemetic efficacy of 2 agents: Akynzeo® plus dexamethasone in patients receiving simultaneously radiotherapy and chemotherapy with weekly cisplatin for at least five weeks.

Ongoing
2
80
Europe
Akynzeo, Tablet, Capsule, hard, Dexamethason, Akynzeo
Department of oncology, Odense University Hospital, Helsinn Healthcare SA
Eligible patients will have a diagnosis of cervical cancer, and be scheduled to receive fractionated radiotherapy and concomitant weekly cisplatin at a dose of ≥ 40 mg/m2 for at least five weeks. Patients must be naïve to both radiotherapy and chemotherapy., Patients entering the study will have a diagnosis of cervical cancer, and be scheduled to receive simultaneously radiotherapy and chemotherapy with weekly infusion of cisplatin for at least 5 weeks., Not possible to specify
 
 
NCT04362449: Comparing the Current Hydration Regimen for the ABC02 Chemotherapy Regimen Versus a Shorter Hydration

Recruiting
2
30
Europe
Shortened hydration time and dispensary of Akynzeo, Standard of care
Imperial College Healthcare NHS Trust, Chugai Pharma UK Limited
Gallbladder Cancer
02/23
02/23
NCT06065722: Prevention of Breakthrough CINV in Patients Receiving Moderately or Highly Emetogenic Chemotherapy

Recruiting
2
100
US
Akynzeo, Olanzapine
Simon Williamson Clinic, Helsinn Healthcare SA
Chemotherapy Induced Nausea and Vomiting
12/23
12/23
NCT03386617: AKY15-HK-301_NEPA Study

Active, not recruiting
2
55
RoW
NEPA
Chinese University of Hong Kong, Princess Margaret Hospital, Hong Kong
Breast Cancer
12/25
12/26
NCT06840769: A Clinical Trial to Assess Safety and Pharmacokinetics of Fosnetupitant 235 mg and Metabolites in Healthy Volunteers

Terminated
1
50
Europe
Fosnetupitant 235 mg solution, Helsinn Fosnetupitant solution, Akynzeo solution, IV Akynzeo®
Helsinn Healthcare SA
Healthy Volunteers
10/23
10/23
ChiCTR2400090026: Clinical effect of different doses of olanzapine combined with triple antiemetic therapy on the prevention of nausea and vomiting caused by high emetogenic chemotherapy for malignant tumors

Not yet recruiting
N/A
400
 
. In the first cycle, 5mg olanzapine combined with triple antiemesis (Akynzeo combined with dexamethasone) was used to prevent nausea and vomiting after chemotherapy, and in the second cycle, 10mg olanzapine combined with triple antiemesis ( Akynzeo combined with dexamethasone) was used to prevent nausea and vomiting after chemotherapy; ; In the first cycle, 10mg olanzapine combined with triple antiemesis (Akynzeo combined with dexamethasone) was used to prevent nausea and vomiting after chemotherapy, and in the second cycle, 5mg olanzapine combined with triple antiemesis ( Akynzeo combined with dexamethasone) was used to prevent nausea and vomiting after chemotherapy;
Zhoukou Center Hospital; Zhoukou Center Hospital
chemotherapy-induced nausea and vomiting
 
 
ChiCTR2400089311: Exploratory study on a single-day low-dose dexamethasone combined with a single or double standard dose of netupitant palonosetron capsules for preventing nausea and vomiting in patients undergoing moderately to highly emetogenic chemotherapy (LD-NEPA1/2 study)

Not yet recruiting
N/A
164
 
Administer a 5mg dexamethasone intravenous injection 30 minutes before chemotherapy and orally take one NEPA capsule; Administer a 8mg dexamethasone intravenous injection 30 minutes before chemotherapy and orally take one NEPA capsule
Zhongshan Hospital Affiliated to Xiamen University; Zhongshan Hospital Affiliated to Xiamen University, Self-funded
chemotherapy-induced nausea and vomiting
 
 
ChiCTR2500097314: A Retrospective Study on the Efficacy and Safety of Oral NEPA Capsules in Preventing Nausea and Vomiting in Nasopharyngeal Carcinoma Patients after Cisplatin Chemotherapy

Completed
N/A
246
 
NA; NA
Affiliated Hospital of Guangdong Medical University; Affiliated Hospital of Guangdong Medical University, Self raised funds
Chemotherapy-Induced Nausea and Vomiting
 
 
Ryaltris (olopatadine/mometasone) / Glenmark
ChiCTR2200058442: A Phase 3 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of GSP 301 Nasal Spray in Adult and Adolescent Chinese Subjects with Seasonal Allergic Rhinitis

Recruiting
3
531
 
Intranasal drug delivery ;Intranasal drug delivery ;Intranasal drug delivery
Beijing Tongren Hospital, Capital Medical University; Grandpharma (China) CO., LTD., Enterprise self-raised
Seasonal Allergic Rhinitis
 
 
NCT06126952: Azelastine Allergen Chamber - Onset of Action Study

Completed
2
84
Canada
Treatment A: Azelastine hydrochloride 0.15% nasal spray (Azelair), Treatment B: Placebo (Azelastine 0.15% vehicle) nasal spray, Treatment C: Ryaltris (Active Control) - mometasone furoate monohydrate and olopatadine hydrochloride nasal spray
MEDA Pharma GmbH & Co. KG
Seasonal Allergic Rhinitis
02/24
03/24
Enweida (envafolimab) / 3DMed, Ascletis
ChiCTR2200060332: Concurrent chemoradiotherapy with or without recombinant human endostatin (Endo) consolidation with envafolimab in patients with stage III unresectable non-small cell lung cancer (NSCLC)

Not yet recruiting
4
72
 
The dose of Endostar is 7.5 mg/m2, continuous intravenous infusion 5 days a week, starting 5 days before radiotherapy, one cycle every 2 weeks, a total of 4 cycles. Synchronous EP program for 3 cycles. Consolidation therapy with enverolimab was started 14 days to 30 days after the end of radiotherap ;3 cycles of radiotherapy synchronous EP program. 14 days to 30 days after the end of radiotherapy, Envolimumab consolidation therapy was started, 400 mg each time, 28 days/time, until disease progression or intolerance, and the longest treatment time was 1 year.
Jiamusi Cancer Hospital; Jiamusi Cancer Hospital, China International Medical Foundation
Stage III unresectable non-small cell lung cancer
 
 
Clinical trial of Envafolimab alone or in combination in patients with advanced solid tumors who have failed first-line therapy containing PD-1 monoclonal antibody, ChiCTR2200066743: A two-cohort, prospective, open clinical trial of Envafolimab monotherapy or combination therapy in patients with advanced solid tumors who failed first-line therapy with PD-1 monoclonal antibody

Not yet recruiting
4
75
 
Treatment with Envafolimab
The First Hospital of China Medical University; The First Hospital of China Medical University, Courtesy of Simcere
Solid tumor
 
 
ChiCTR2300067590: A single-arm, open-label, phase II study of Eutidrone versus Cisplatin/Carboplatin combined with Envafolimab in patients with advanced non-small cell lung cancer

Recruiting
4
51
 
Eutidrone versus Cisplatin/Carboplatin combined with Envafolimab
The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Cancer Hospital); The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Cancer Hospital), Self-raised
NSCLC
 
 
ChiCTR2500100348: Neoadjuvant Envafolimab plus Chemotherapy in Locally Advanced Head and Neck Carcinoma: an open-label clinical trial

Recruiting
4
38
 
Neoadjuvant Envafolimab plus Chemotherapy
Peking University Hospital of Stomatology; Peking University Hospital of Stomatology, Self raised funds
squamous cell carcinoma of the head and neck
 
 
KN035-BTC, NCT03478488: Programmed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTC

Active, not recruiting
3
480
RoW
KN035 plus Gemcitabine & oxaliplatin, Experimental, Gemcitabine & oxaliplatin, Active Comparator
3D Medicines (Sichuan) Co., Ltd.
Biliary Tract Neoplasms
09/24
12/26
PRECAM-R, NCT05752136: Preoperative Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Rectal Adenocarcinoma

Recruiting
3
108
RoW
Envafolimab
Sir Run Run Shaw Hospital
Rectal Cancer
04/25
12/28
KN035-CN-017, NCT06123754: Phase III Study of Envafolimab Versus Placebo Plus Chemotherapy in Resectable Stage III NSCLC

Recruiting
3
390
RoW
Envalfolimab subcutaneously injected+Platinum-based doublet chemotherapy intravenous injection, Experimental, placebo subcutaneously injected +Platinum-based doublet chemotherapy intravenous injection, Active Comparator
3D Medicines (Sichuan) Co., Ltd.
Non-small Cell Lung Cancer
12/25
09/27
NCT06959693: A Clinical Study to Evaluate the Efficacy and Safety of Envafolimab Combined With Cetuxima-βand mFOLFOX6 in Patients With MSS, RAS/BRAF Wild-Type Metastatic Colorectal Cancer (mCRC)

Not yet recruiting
2/3
590
RoW
Cetuxima-β, Envafolimab, mFOLFOX6
Sun Yat-sen University
Metastatic Colorectal Cancer (CRC)
09/28
06/30
ChiCTR1800017857: KN035 prospective single arm phase II clinical study on efficacy and safety in the treatment of patients with advanced multiple primary tumors

Not yet recruiting
2
20
 
KN035
Renji Hospital Affiliated to Medical School of Shanghai Jiaotong University; Renji Hospital, Shanghai shenkang hospital development center clinical science and technology innovation project - municipal hospital clinical research and cultivation project
Multiple primary tumors
 
 
CISLD-12, NCT05213221: Study on Therapeutic Effect of Combination of Envafolimab, Lenavatinib and TACE in Advanced HCC Patients

Completed
2
39
RoW
Envafolimab, TACE, Lenvatinib
Zhejiang University
Advanced Hepatocellular Carcinoma
09/22
06/23
NCT05298020: Envafolimab Combined With Endostar and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer

Not yet recruiting
2
20
RoW
Envafolimab, Immunotherapy, Endostar, endostatin, Nab paclitaxel, Chemotherapy, Gemcitabine
The Affiliated Hospital of Xuzhou Medical University
Advanced Pancreatic Cancer
12/22
04/23
ENLEN-OC-001, NCT05422183: Envafolimab, Lenvatinib Combined With VP-16 in Platinum-resistant Recurrent Epithelial Ovarian Cancer

Not yet recruiting
2
20
RoW
Envafolimab, Immunotherapy, Lenvatinib, Tyrosine kinase inhibitors, VP-16, Chemotherapy
Zhongda Hospital
Ovarian Cancer, Epithelial
12/22
12/23
NCT05237349: Envafolimab Combined With Chemotherapy in Metastatic or Recurrent Gastric Adenocarcinoma

Recruiting
2
38
RoW
Envafolimab, Immunotherapy, Oxaliplatin, Chemotherapy, S1
Liangjun Zhu M.M., Zhangjiagang First People's Hospital
Metastatic or Recurrent Gastric Adenocarcinoma
12/24
12/24
PRECAM, NCT05216653: Preoperative Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Rectal Adenocarcinoma

Completed
2
32
RoW
Envafolimab, KN053, Oxaliplatin, Capecitabine, Short-course Radiation, TME surgery, total mesorectal excision
Sir Run Run Shaw Hospital
MSS Locally Advanced Rectal Adenocarcinoma
03/23
03/25
SLKYLX2023-006, NCT06239870: Single-arm, Single-center, Exploratory Phase II Clinical Study of Envafolimab Combined With Chemoradiotherapy in the Treatment of Locally Advanced pMMR/MSS Rectal Cancer

Recruiting
2
35
RoW
Envafolimab combined with chemoradiotherapy in the whole course of neoadjuvant therapy
Yunnan Cancer Hospital, Beijing Bethune Charitable Foundation
Envafolimab Combined With Chemoradiotherapy in the Treatment of Locally Advanced pMMR/MSS Rectal Cancer
09/25
09/25
NCT05335460: To Determine the Efficacy and Safety of Envafolimab Combined With XELOX for Locally Advanced Colon Cancer

Not yet recruiting
2
36
NA
Envafolimab, XELOX( Oxaliplatin 130mg/m2,ivgtt, Q3w capecitabine 1000mg/m2, p.o Q3w)
Fujian Cancer Hospital
Colon Cancer
05/23
05/24
NSCLC-LXL002, NCT05360979: A Clinical Study of Immunotherapy Combined With Chemotherapy and Anti-angiogenic Therapy in Operable NSCLC

Enrolling by invitation
2
42
RoW
envafolimab, recombinant human endostatin, chemotherapy
Second Xiangya Hospital of Central South University
Non-small Cell Lung Cancer
05/23
05/25
NCT05551247: Envafolimab Combined With Endostatin in Recurrent or Metastatic MSS-type Colorectal Cancer

Not yet recruiting
2
30
NA
Envafolimab, recombinant human endostatin (endostatin)
First Affiliated Hospital Xi'an Jiaotong University
Colorectal Neoplasms
06/23
06/24
ChiCTR1900021607: A Phase II, Single-arm and Open-labelled Clinical Study of Anti-PD-L1 Antibody KN035 Combined with Trastuzumab and Docetaxel in the Treatment of HER2-positive Advanced Breast Cancer

Recruiting
2
59
 
Conventional chemotherapy (TH regimen) combined with KN035 5mg/kg/3w
Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Natural Science Foundation of China (81622036)
breast cancer
 
 
ASC-ASC22-II-CTP-01, NCT04465890: A Phase II Study of Subcutaneously Injected PD-L1 Antibody ASC22 in Chronic Hepatitis B Patients

Completed
2
207
RoW
ASC22, sodium chloride
Ascletis Pharmaceuticals Co., Ltd., Peking University First Hospital, Beijing Clinical Service Center
Chronic Hepatitis b
08/24
08/24
NCT05148195: A Phase II Study of Envofolimab and BD0801 With/Without Chemotherapy in Patients With Advanced Solid Tumors

Terminated
2
86
RoW
Envofolimab, BD0801, Docetaxel, Irinotecan, Leucovorin calcium, 5-Fluorouridine
Jiangsu Simcere Pharmaceutical Co., Ltd.
Advanced Solid Tumor
07/23
07/23
NCT05387681: Preoperative Short Course Radiotherapy With Envafolimab, Endostatin and SOX Regimen in Locally Advanced Gastric

Not yet recruiting
2
35
NA
Envafolimab, Endostatin
Wuhan Union Hospital, China
Gastric/Gastroesophageal Junction Adenocarcinoma, Radiotherapy, Immunotherapy
07/23
12/25
NCT05529355: Effect and Safety of Envafolimab Combined With Endostar/S-1 in Second-line of Advanced Non-small Cell Lung Cancer

Not yet recruiting
2
45
NA
Envafolimab plus Endostar and S-1, Envafolimab combined with Recombinant Human Endostatin Injection/Tegafur,Gimeracil and Oteracil Porassium Capsules, Envafolimab plus Endostar, Envafolimab combined with Recombinant Human Endostatin Injection, Envafolimab plus S-1, Envafolimab combined with Tegafur,Gimeracil and Oteracil Porassium Capsules
Anhui Chest Hospital
Carcinoma, Non-Small-Cell Lung
09/23
09/23
NCT05582109: Envafolimab, Lenvatinib Combined With TACE in the Treatment of Unresectable Locally Advanced Hepatocellular Carcinoma

Not yet recruiting
2
30
NA
Envafolimab, Lenvatinib Combined With TACE
Tianjin Medical University Cancer Institute and Hospital
Objective Response Rate (ORR)
10/23
10/25
NCT05068427: Trial of Chidamide in Combination With Envafolimab in Patients With PD-1 Inhibitor Resistant Advanced NSCLC.

Completed
2
34
RoW
Chidamide, CS055, Envafolimab, KN035
Chipscreen Biosciences, Ltd.
Non Small Cell Lung Cancer
02/23
05/24
NCT05243355: Envafolimab Combined With Chemotherapy and Recombinant Human Endostatin in the First-line Treatment of Sq-NSCLC

Recruiting
2
46
RoW
"Envafolimab" and "Chemotherapy" and "Recombinant Human Endostatin"
Qilu Hospital of Shandong University
Squamous Non-small Cell Lung Cancer
12/23
12/24
NCT05330143: Study to Evaluate Safety, Tolerance and Efficacy of ASC22 Combined With ART in Subjects With HIV

Completed
2
19
RoW
ASC22 1mg/kg, KN035, ASC22 2.5mg/kg, Antiretroviral Therapy, Placebo
Ascletis Pharmaceuticals Co., Ltd.
HIV-1-infection, HIV Infections, PD-L1 Gene Mutation
05/24
05/24
NCT06143579: A Study of HAIC Combined With Lenvatinib and Envolizumab in Potentially Resectable Hepatocellular Carcinoma

Not yet recruiting
2
48
NA
FOLFOX-HAIC+Lenvatinib+Envolizumab, KN035
Sun Yat-sen University
Potentially Resectable Hepatocellular Carcinoma
03/25
12/26
NCT05552651: Envafolimab Combined With Chemotherapy in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma

Not yet recruiting
2
40
NA
Envafolimab, Albumin-Bound Paclitaxel, Carboplatin
Tao Jiang
Esophageal Squamous Cell Carcinoma
12/23
12/23
NCT03667170: KN035 for dMMR/MSI-H Advanced Solid Tumors

Recruiting
2
200
RoW
KN035
3D Medicines (Sichuan) Co., Ltd.
Solid Tumor
12/25
12/26
NCT05112991: Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer

Recruiting
2
108
RoW
Envafolimab+Lenvatinib, Envafolimab
3D Medicines (Sichuan) Co., Ltd.
Advanced Endometrial Cancer
12/25
12/25
ESTIMATE, ChiCTR2400079718: Single-arm, single-center, exploratory Phase II clinical study of Envafolimab combined with chemoradiotherapy in the treatment of locally advanced pMMR/MSS rectal cancer

Recruiting
2
35
China
Enweida (envafolimab) - 3DMed, Tracon Pharma, Ascletis, capecitabine - Generic mfg.
Yunnan Cancer Hospital, Beijing Bethune Charitable Foundation
pMMR/MSS locally advanced rectal cancer
 
 
NCT06218004: Envafolimab Combined With Chemotherapy in Neoadjuvant and Conversion Therapy for Head and Neck Squamous Cell Carcinoma

Not yet recruiting
2
40
NA
Envafolimab combined with chemotherapy, Envafolimab
Hairong Liu
Efficacy and Safety
12/25
12/25
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ISC 17536 / Glenmark
2013-002728-17: A 4 week study to evaluate efficacy, safety and tolerability of Inhaled GRC 17536 in Patients with Refractory Chronic Cough

Ongoing
2
48
Europe
GRC 17536 potassium powder for inhalation, GRC 17536 potassium,
Glenmark Pharmaceuticals SA, Glenmark Pharmaceuticals SA
Refractory Chronic Cough.
 
 
telazorlimab (ISB 830) / Astria Therap
2018-000783-29: A Study of GBR 830 in Adult Patients with Atopic Dermatitis

Not yet recruiting
2
468
Europe
ISB 830, Powder for solution for infusion
Ichnos Sciences SA, Inchos Sciences SA (renamed from Glenmark Pharmaceuticals SA), Ichnos Sciences SA, Inchos Sciences SA
Moderate to severe atopic dermatitis, Moderate to severe eczema, Diseases [C] - Immune System Diseases [C20]
 
 
Cibinqo (abrocitinib) / Pfizer
NCT05602207: Effects of Abrocitinib in Subjects With Atopic Dermatitis With an Unsatisfactory Response After Treatment With Dupilumab

Completed
4
24
Canada, US
Abrocitinib, CIBINQO
Innovaderm Research Inc.
Atopic Dermatitis
12/24
01/25
DermAtOmics-II, NCT06366932: Optimization of Atopic Dermatitis Treatment That Requires Second-line Systemic Therapy Through Predictive Models

Recruiting
4
150
Europe
Second-line systemic treatment, Dupilumab, Tralokinumab, Upadacitinib, Baricitinib, Abrocitinib, Folllow-up of second-line systemic treatment already started
Instituto de Investigación Hospital Universitario La Paz
Atopic Dermatitis
09/25
09/25
ChiCTR2400086045: Registry of Chinese atopic dermatitis (AD) patients receiving abrocitinib

Recruiting
4
2000
 
None
The First Hospital of China Medical University; The First Hospital of China Medical University, China Primary Health Care Foundation
Atopic dermatitis (AD)
 
 
NCT05375929 / 2024-000141-26: A Study to Learn About Abrocitinib Tablets in People With Atopic Dermatitis in India

Completed
3
200
RoW
Abrocitinib 100 mg, Abrocitinib 200 mg
Pfizer, Pfizer Inc.
Atopic Dermatitis
06/23
03/24
2024-000141-26: The purpose of this clinical trial is to learn about the safety and how well the study medicine (called Abrocitinib) works for the potential treatment of moderate to severe Atopic Dermatitis (AD) in India.

Not yet recruiting
3
200
RoW
Abrocitinib, PF-04965842, Film-coated tablet, Cibinqo
Pfizer Inc., Pfizer Inc.
Moderate to severe atopic dermatitis, Atopic dermatitis is also known as atopic eczema. It is a type of inflammation of the skin that results in itchy, red, swollen, and cracked skin., Diseases [C] - Skin and Connective Tissue Diseases [C17]
 
 
NCT06807268: A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema

Not yet recruiting
3
150
Japan, US
Abrocitinib, PF-04965842, Placebo
Pfizer
Eczema
05/27
05/27
NCT06807281: A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema

Not yet recruiting
3
500
NA
Abrocitinib, PF-04965842
Pfizer
Atopic Dermatitis
02/32
02/32
JADE EXTEND, NCT03422822 / 2017-004851-22: Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

Hourglass Jul 2021 - Sep 2021 : From JADE EXTEND trial for patients 12 years and older with atopic dermatitis
Active, not recruiting
3
3164
Europe, Canada, Japan, US, RoW
Abrocitinib 100 mg, Abrocitinib 200 mg, Placebo
Pfizer
Dermatitis, Atopic
12/25
12/25
NCT05696795: Janus Kinase Inhibition in Sarcoidosis

Completed
2
10
US
Abrocitinib 200 mg
Yale University, Pfizer
Sarcoidosis
04/25
04/25
NCT06283550: Efficacy, Safety, and Tolerability of Abrocitinib in Subjects With Moderate to Severe Chronic Hand Eczema Refractory to Corticosteroid Therapy

Active, not recruiting
2
84
Canada
Abrocitinib 200 mg, CIBINQO, Abrocitinib 100 mg, Placebo, Inert tablet
Innovaderm Research Inc.
Chronic Hand Eczema
11/25
12/25
NCT05650736: Janus Kinase Inhibition in Granuloma Annulare

Active, not recruiting
2
10
US
Abrocitinib 200 mg
William Damsky, Yale University, Pfizer
Granuloma Annulare
05/24
07/25
CLEAR-LC, NCT06597396: Study to Investigate the Efficacy of Abrocitinib in Adult Participants with Severe Fatigue from Post COVID Condition/Long COVID

Recruiting
2
90
US
Abrocitinib, Placebo
Beth Israel Deaconess Medical Center, Pfizer
Post-COVID Condition, Fatigue Symptom
01/26
06/26
NCT05743244: Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D)

Recruiting
2
78
Canada, US, RoW
Abrocitinib 200 MG Oral Tablet, CIBINQO, Ritlecitinib, Placebo
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Pfizer
Diabetes Mellitus, Type 1
06/26
06/27
NCT05069831: JAK Inhibition in Food Allergy

Completed
1
71
US
Abrocitinib
Icahn School of Medicine at Mount Sinai
Food Allergy
06/25
06/25
TEN, NCT06119490: Evaluation of the Efficacy and Safety of Methylprednisolone Combined With the JAK Inhibitors in the Treatment of Toxic Epidermal Necrolysis

Recruiting
1
30
RoW
Abrocitinib, Solu-Medrol®, Tofacitinib
Peng Zhang
Toxic Epidermal Necrolysis
07/26
09/26
NCT04564755 / 2020-003610-12: Abrocitinib Expanded Access Protocol in Adolescents and Adults With Moderate to Severe Atopic Dermatitis

No Longer Available
N/A
Europe, Canada, US, RoW
abrocitinib
Pfizer
Atopic Dermatitis
 
 
NCT05466578: Pre-approval Single-patient Expanded Access for Abrocitinib (PF-04965842)

Available
N/A
NA
abrocitinib
Pfizer, In Expanded Access, treating physicians are the Sponsor
Severe Uncontrolled Atopic Dermatitis
 
 
AbroSkib, NCT05140239: Effects of Abrocitinib Treatment on Skin Barrier Function

Active, not recruiting
N/A
20
Europe
No Intervention
Prof. Dr. Stephan Weidinger
Atopic Dermatitis
09/24
06/25
ATTRACT, NCT06353087: Abrocitinib Taiwan Treatment Pattern and Real World Study in ATopiC Dermatitis ( Registry)

Recruiting
N/A
200
RoW
Pfizer
Dermatitis, Atopic, Dermatitis, Eczema, Skin Diseases, Immune System Diseases, Janus Kinase Inhibitors
05/26
05/26
RWE, NCT06573593: Efficacy and Safety of JAK Inhibitors in Patients With AA: Study

Recruiting
N/A
150
RoW
Tofacitinib, Baricitinib, Ruxolitinib, Upadacitinib, Abrocitinib, Ritlecitinib
Second Affiliated Hospital, School of Medicine, Zhejiang University
Alopecia Areata, Janus Kinase Inhibitors
12/26
12/26
ChiCTR2500097331: Study on the microscopic characteristics of skin blood vessels in inflammatory skin diseases and the efficacy and safety of abrocitinib tablets combined with Crisborole ointment in the treatment of moderate to severe atopic dermatitis

Completed
N/A
300
 
None; None; The patient takes 100mg of Abrocitinib once daily and applies Crisaborole ointment twice daily for a duration of three months.
China-Japan Friendship Hospital; The Beijing Qingnang Huimin Medical Research Institute Co., Ltd., Horizontal project
Atopic Dermatitis
 
 
NCT05250115: A Study to Learn About Abrocitinib in Adult Patients With Moderate to Severe Atopic Dermatitis

Terminated
N/A
112
Europe
Pfizer
Dermatitis, Atopic
07/24
07/24
ChiCTR2500098251: Abrocitinib in the Treatment of Glucocorticoid-Refractory Acute Urticaria: A Case Series

Recruiting
N/A
5
 
Zhejiang Provincial Tongde Hospital; Zhejiang Provincial Tongde Hospital, Self-funded
Acute urticaria
 
 
NCT06899204: Real World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate Response to Previous Biologic Therapies.

Not yet recruiting
N/A
150
NA
Abrocitinib, Cibinqo
Pfizer
Atopic Dermatitis, Atopic Dermatitis, Unspecified, Dermatitis, Atopic
07/26
08/26
ChiCTR2400090334: Efficacy and Safety of Abrocitinib and Upadacitinib in the Treatment of Children (Aged Below 12) with Moderate to Severe Atopic Dermatitis: A Real World Study

Recruiting
N/A
25
 
therapeutic agents: abrocitinib or upadacitinib
Guangzhou Dermatology Hospital; Guangzhou Dermatology Hospital, Project Fund
atopic dermatitis
 
 
ChiCTR2500097613: To analyze real-world data of abrocitinib in the treatment of adolescents with moderate-to-severe atopic dermatitis (AD) in Guangzhou, China

Recruiting
N/A
60
 
Guangzhou Dermatology Hospital; Guangzhou Dermatology Hospital, Self-funded
atopic dermatitis
 
 
ADAIR, NCT05689151: A Study to Learn About Abrocitinib in Adult Patients With Moderate to Severe Atopic Dermatitis.

Recruiting
N/A
183
Europe
Abrocitinib
Pfizer
Atopic Dermatitis, Eczema
06/26
05/27
ChiCTR2400089103: Exploration and Validation of the Targeted Treatment Protocol for Atopic Dermatitis in China

Not yet recruiting
N/A
200
 
Administer 100 mg of abrocitinib orally once daily to the patient.; Administer 200 mg of abrocitinib orally once daily to the patient.; Administer 300 mg of Dupixent by injection every two weeks to the patient.
Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College; Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Pfizer general research grant No.78229835
Atopic Dermatitis
 
 
NCT05387980: A Study to Learn About the Study Medicine (CIBINQO) in People With Atopic Dermatitis.

Recruiting
N/A
1200
Japan
CIBINQO
Pfizer
Atopic Dermatitis
08/28
08/28
NCT05391061: A Study to Learn About the Study Medicine (Called Cibinqo) in People With Atopic Dermatitis

Recruiting
N/A
1100
RoW
Abrocitinib, Cibinqo
Pfizer
Dermatitis, Atopic
11/27
11/27
NCT03358693: Molecular Signatures in Inflammatory Skin Disease

Recruiting
N/A
300
Europe
Ustekinumab, Infliximab, Secukinumab, Dupilumab, Brodalumab, Ixekizumab, Baricitinib, Abrocitinib, Upadacitinib, Tralokinumab
Prof. Dr. Stephan Weidinger
Atopic Dermatitis, Psoriasis
12/27
12/28
NCT05721937: A Study of How Safe Abrocitinib (CIBINQO) is in Pregnant Women and Their Offspring

Recruiting
N/A
400
US
Abrocitinib
Pfizer, PPD Development, LP
Atopic Dermatitis
12/27
12/27
Winlevi (clascoterone cream 1%) / Cosmo Pharma
NCT06415305: A Study Evaluating the Efficacy and Safety of Clascoterone Cream 1% in Skin of Color Patients With Acne

Completed
4
10
US
Winlevi (clascoterone) 1% cream
Sun Pharmaceutical Industries Limited
Acne Vulgaris
04/24
01/25
NCT06336629: A Study Assessing the Efficacy of Combined Use of Clascoterone 1% Cream and Duac Gel (Benzoyl Peroxide/Clindamycin) for the Treatment of Acne

Completed
4
10
US
Winlevi (clascoterone) 1% & Duac gel
Sun Pharmaceutical Industries Limited
Acne Vulgaris
07/24
07/24
NCT06336603: A Study Assessing the Efficacy of Combined Use of Clascoterone 1% Cream and Adapalene 0.3% for the Treatment of Acne

Completed
4
20
US
Winlevi (clascoterone) 1% & Adapalene 0.3% gel
Sun Pharmaceutical Industries Limited
Acne Vulgaris
10/24
10/24
NCT06415292: A Study to Evaluate the Impact of Clascoterone 1% Cream on Skin Barrier Properties in Acne Prone Patients

Completed
4
50
US
Winlevi (clascoterone) 1% cream
Sun Pharmaceutical Industries Limited
Acne Vulgaris
12/23
12/23
NCT06415279: A Study to Evaluate the Reduction in Sebum (Skin Oil) Induced by Clascoterone Cream 1% in Acne Patients

Completed
4
40
US
Winlevi (clascoterone) 1% cream
Sun Pharmaceutical Industries Limited
Acne Vulgaris
02/25
02/25
NCT06425900: A Study to Assess Sebaceous Gland Changes and Constituents of Sebum (Skin Oil) Induced by Clascoterone 1% Cream in Acne Patients

Active, not recruiting
4
10
US
Winlevi (Clascoterone) cream 1%
Sun Pharmaceutical Industries Limited
Acne Vulgaris
09/25
09/25
2023-000463-32: Study to Evaluate the Safety and Efficacy of CB-03-01 Cream, 1% in Subjects with Facial Acne Vulgaris

Not yet recruiting
3
708
US, RoW
cortexolone 17alpha-propionate, CB-03-01, Cream
CASSIOPEA SpA, CASSIOPEA SpA
Facial Acne Vulgaris, Facial Acne, Diseases [C] - Skin and Connective Tissue Diseases [C17]
 
 
NCT06403501: Efficacy and Safety of Clascoterone Cream 1% in Facial Acne Vulgaris

Recruiting
3
692
RoW
Clascoterone, Winlevi (brand name), Vehicle cream
Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd.
Acne Vulgaris
02/25
02/25
SCALP1, NCT05910450: A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss

Recruiting
3
726
US, RoW
Clascoterone 5% solution, CB-03-01 5% solution, Vehicle solution, Vehicle
Cassiopea SpA, Ergomed PLC, Pharmapace Inc, Canfield Scientific Inc., ICON Clinical Research
Alopecia, Androgenetic
10/24
04/25
SCALP2, NCT05914805: A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss

Recruiting
3
726
Europe, US
Clascoterone 5% solution, CB-03-01 5% solution, Vehicle solution, Vehicle
Cassiopea SpA, Ergomed PLC, Pharmapace Inc, Canfield Scientific Inc., ICON Clinical Research
Alopecia, Androgenetic
08/24
03/25
2023-000461-13: A Phase 2 Dose Escalating Study to Evaluate the Safety and Efficacy of CB-03-01 Cream in Subjects With Facial Acne Vulgaris

Not yet recruiting
2
363
US
cortexolone 17alpha-propionate, CB-03-01, Cream
Intrepid Therapeutics Inc., Cosmo SpA
Facial Acne Vulgaris, Facial Acne, Diseases [C] - Skin and Connective Tissue Diseases [C17]
 
 
NCT06286397: Topical Anti-Androgens in Pilonidal Sinus Disease

Not yet recruiting
2
75
US
1% Clascoterone, Vehicle Cream
University of Pennsylvania
Pilonidal Disease, Pilonidal Disease of Natal Cleft, Pilonidal Sinus, Pilonidal Cyst
08/27
12/27
NCT06952517: Efficacy and Safety of Topical Clascoterone (WINLEVI) Cream 1% in Patients With Facial Acneiform Rosacea

Recruiting
2
20
US
Clascoterone Cream 1%, WINLEVI
Narrows Institute for Biomedical Research, Sun Pharmaceutical Industries Limited
Papular-pustular Rosacea, Papulopustular Rosacea (PPR), Papulopustular Rosacea
09/25
09/25
NCT05891795: Clascoterone for Steroid-related Acne Vulgaris in Transgender Male Patients Receiving Masculinizing Hormone Therapy

Recruiting
1/2
18
US
Clascoterone 1% Top Cream, Vehicle
Stanford University
Acne Vulgaris
12/25
12/25
NCT06454708: Pharmacokinetics, Safety and Tolerability of Clascoterone Cream 1% in Healthy Chinese Adult Subjects

Completed
1
12
RoW
Clascoterone Cream 1%
Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd.
Acne Vulgaris
08/24
08/24
Akynzeo oral (netupitant/palonesteron FDC) / Helsinn
ACTRN12620000455965p: Akynzeo for post-operative nausea and vomiting after bariatric surgery.

Not yet recruiting
4
86
 
St Vincent's Hospital Melbourne, St Vincent's Hospital Melbourne Research Endowment Fund
morbid obesity; Post-operative nausea and vomitting
 
 
ACTRN12620000455965: Akynzeo for post-operative nausea and vomiting after bariatric surgery.

Recruiting
4
160
 
St Vincent's Hospital Melbourne, St Vincent's Hospital Melbourne Research Endowment Fund
morbid obesity, Post-operative nausea and vomitting
 
 
NOEME, NCT06726291: Akynzeo as Antiemetic Treatment in Patients With Endometrial Cancer

Recruiting
4
84
Europe
NEPA (300mg netupitant/0.5mg palonosetron)
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Endometrial Cancer
12/25
06/26
NCT04817189 / 2019-004686-41: Oral Akynzeo® Vs Standard of Care in Preventing CINV in High-risk MEC Patients (MyRisk)

Completed
4
414
Europe, RoW
NEPA (300mg netupitant/0.5mg palonosetron), Akynzeo® capsules, Granisetron, 2 mg (oral) or 1 mg (IV) OR Palonosetron, 0.5 mg (oral), 0.25mg (IV) OR Ondansetron, 16 mg (oral) or 8 mg (IV) OR Dolasetron 100 mg (oral) OR Tropisetron 5 mg (oral or IV), 5-HT3 RA, Dexamethasone, 8 mg (oral) or equivalent IV dose, corticosteroid
Helsinn Healthcare SA
Chemotherapy-induced Nausea and Vomiting
07/24
07/24
NCT06331520: NEPA Combined With Olanzapine, Dexamethasone-sparing for the Effect of CINV in Patients Receiving HEC Regimens

Not yet recruiting
3
627
NA
Netupitant / Palonosetron Oral Capsule [Akynzeo], Olanzapine, Dexamethasone Oral
Fudan University
Chemotherapy-induced Nausea and Vomiting, Highly Emetogenic Chemotherapy
05/25
05/26
NCT03367572: Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer

Completed
3
1351
US
Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Fluorodelta, Fortecortin, Gammacorten, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, Visumetazone, Laboratory Biomarker Analysis, Netupitant/Palonosetron Hydrochloride, Akynzeo, Olanzapine, LY 170053, Zydis, Zyprexa, Zyprexa Zydis, Placebo, placebo therapy, PLCB, sham therapy, Prochlorperazine, RP 6140, SKF-4657, Quality-of-Life Assessment, Quality of Life Assessment
University of Rochester NCORP Research Base, National Cancer Institute (NCI)
Breast Carcinoma
04/24
04/24
NCT03668639: Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin

Recruiting
2/3
80
Europe
Akynzeo, Dexamethasone
Christina Ruhlmann, Helsinn Healthcare SA
Chemotherapy-induced Nausea and Vomiting, Adverse Event, Cervical Cancer
03/23
04/23
2015-003318-26: Phase II, open-label, not comparative, multicenter study of multiple doses of NEPA (Netupitant+Palonosetron) in preventing chemotherapy induced nausea and vomiting(CINV) in patient with Non Hodgkin’s Lymphomareceiving salvage chemotherapy followed by high dose chemotherapy and autologous hematopoietic stem cells support. Studio di fase II, in aperto, non comparativo, multicentrico, di dosi ripetute di NEPA (netupitant + palonosetron) nella prevenzione della nausea ed il vomito indotti da chemioterapia (CINV) in pazienti con Linfoma Non-Hodgkin trattati con chemioterapia di salvataggio seguita da alte dosi di chemioterapia con supporto di cellule staminali ematopoietiche

Ongoing
2
81
Europe
AKYNZEO, EU/1/15/1001/001, Capsule, hard, AKYNZEO
ASSOCIAZIONE SALENTINA ANGELA SERRA ONLUS, ITALFARMACO S.P.A.
NON HODGKIN'S LYMPHOMA LINFOMA NON HODGKIN, NON HODGKIN'S LYMPHOMA LINFOMA NON HODGKIN, Diseases [C] - Cancer [C04]
 
 
2017-004031-37: A study to investigate the safety and antiemetic efficacy of 2 agents: Akynzeo® plus dexamethasone in patients receiving simultaneously radiotherapy and chemotherapy with weekly cisplatin for at least five weeks.

Ongoing
2
80
Europe
Akynzeo, Tablet, Capsule, hard, Dexamethason, Akynzeo
Department of oncology, Odense University Hospital, Helsinn Healthcare SA
Eligible patients will have a diagnosis of cervical cancer, and be scheduled to receive fractionated radiotherapy and concomitant weekly cisplatin at a dose of ≥ 40 mg/m2 for at least five weeks. Patients must be naïve to both radiotherapy and chemotherapy., Patients entering the study will have a diagnosis of cervical cancer, and be scheduled to receive simultaneously radiotherapy and chemotherapy with weekly infusion of cisplatin for at least 5 weeks., Not possible to specify
 
 
NCT04362449: Comparing the Current Hydration Regimen for the ABC02 Chemotherapy Regimen Versus a Shorter Hydration

Recruiting
2
30
Europe
Shortened hydration time and dispensary of Akynzeo, Standard of care
Imperial College Healthcare NHS Trust, Chugai Pharma UK Limited
Gallbladder Cancer
02/23
02/23
NCT06065722: Prevention of Breakthrough CINV in Patients Receiving Moderately or Highly Emetogenic Chemotherapy

Recruiting
2
100
US
Akynzeo, Olanzapine
Simon Williamson Clinic, Helsinn Healthcare SA
Chemotherapy Induced Nausea and Vomiting
12/23
12/23
NCT03386617: AKY15-HK-301_NEPA Study

Active, not recruiting
2
55
RoW
NEPA
Chinese University of Hong Kong, Princess Margaret Hospital, Hong Kong
Breast Cancer
12/25
12/26
NCT06840769: A Clinical Trial to Assess Safety and Pharmacokinetics of Fosnetupitant 235 mg and Metabolites in Healthy Volunteers

Terminated
1
50
Europe
Fosnetupitant 235 mg solution, Helsinn Fosnetupitant solution, Akynzeo solution, IV Akynzeo®
Helsinn Healthcare SA
Healthy Volunteers
10/23
10/23
ChiCTR2400090026: Clinical effect of different doses of olanzapine combined with triple antiemetic therapy on the prevention of nausea and vomiting caused by high emetogenic chemotherapy for malignant tumors

Not yet recruiting
N/A
400
 
. In the first cycle, 5mg olanzapine combined with triple antiemesis (Akynzeo combined with dexamethasone) was used to prevent nausea and vomiting after chemotherapy, and in the second cycle, 10mg olanzapine combined with triple antiemesis ( Akynzeo combined with dexamethasone) was used to prevent nausea and vomiting after chemotherapy; ; In the first cycle, 10mg olanzapine combined with triple antiemesis (Akynzeo combined with dexamethasone) was used to prevent nausea and vomiting after chemotherapy, and in the second cycle, 5mg olanzapine combined with triple antiemesis ( Akynzeo combined with dexamethasone) was used to prevent nausea and vomiting after chemotherapy;
Zhoukou Center Hospital; Zhoukou Center Hospital
chemotherapy-induced nausea and vomiting
 
 
ChiCTR2400089311: Exploratory study on a single-day low-dose dexamethasone combined with a single or double standard dose of netupitant palonosetron capsules for preventing nausea and vomiting in patients undergoing moderately to highly emetogenic chemotherapy (LD-NEPA1/2 study)

Not yet recruiting
N/A
164
 
Administer a 5mg dexamethasone intravenous injection 30 minutes before chemotherapy and orally take one NEPA capsule; Administer a 8mg dexamethasone intravenous injection 30 minutes before chemotherapy and orally take one NEPA capsule
Zhongshan Hospital Affiliated to Xiamen University; Zhongshan Hospital Affiliated to Xiamen University, Self-funded
chemotherapy-induced nausea and vomiting
 
 
ChiCTR2500097314: A Retrospective Study on the Efficacy and Safety of Oral NEPA Capsules in Preventing Nausea and Vomiting in Nasopharyngeal Carcinoma Patients after Cisplatin Chemotherapy

Completed
N/A
246
 
NA; NA
Affiliated Hospital of Guangdong Medical University; Affiliated Hospital of Guangdong Medical University, Self raised funds
Chemotherapy-Induced Nausea and Vomiting
 
 
Ryaltris (olopatadine/mometasone) / Glenmark
ChiCTR2200058442: A Phase 3 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of GSP 301 Nasal Spray in Adult and Adolescent Chinese Subjects with Seasonal Allergic Rhinitis

Recruiting
3
531
 
Intranasal drug delivery ;Intranasal drug delivery ;Intranasal drug delivery
Beijing Tongren Hospital, Capital Medical University; Grandpharma (China) CO., LTD., Enterprise self-raised
Seasonal Allergic Rhinitis
 
 
NCT06126952: Azelastine Allergen Chamber - Onset of Action Study

Completed
2
84
Canada
Treatment A: Azelastine hydrochloride 0.15% nasal spray (Azelair), Treatment B: Placebo (Azelastine 0.15% vehicle) nasal spray, Treatment C: Ryaltris (Active Control) - mometasone furoate monohydrate and olopatadine hydrochloride nasal spray
MEDA Pharma GmbH & Co. KG
Seasonal Allergic Rhinitis
02/24
03/24
Enweida (envafolimab) / 3DMed, Ascletis
ChiCTR2200060332: Concurrent chemoradiotherapy with or without recombinant human endostatin (Endo) consolidation with envafolimab in patients with stage III unresectable non-small cell lung cancer (NSCLC)

Not yet recruiting
4
72
 
The dose of Endostar is 7.5 mg/m2, continuous intravenous infusion 5 days a week, starting 5 days before radiotherapy, one cycle every 2 weeks, a total of 4 cycles. Synchronous EP program for 3 cycles. Consolidation therapy with enverolimab was started 14 days to 30 days after the end of radiotherap ;3 cycles of radiotherapy synchronous EP program. 14 days to 30 days after the end of radiotherapy, Envolimumab consolidation therapy was started, 400 mg each time, 28 days/time, until disease progression or intolerance, and the longest treatment time was 1 year.
Jiamusi Cancer Hospital; Jiamusi Cancer Hospital, China International Medical Foundation
Stage III unresectable non-small cell lung cancer
 
 
Clinical trial of Envafolimab alone or in combination in patients with advanced solid tumors who have failed first-line therapy containing PD-1 monoclonal antibody, ChiCTR2200066743: A two-cohort, prospective, open clinical trial of Envafolimab monotherapy or combination therapy in patients with advanced solid tumors who failed first-line therapy with PD-1 monoclonal antibody

Not yet recruiting
4
75
 
Treatment with Envafolimab
The First Hospital of China Medical University; The First Hospital of China Medical University, Courtesy of Simcere
Solid tumor
 
 
ChiCTR2300067590: A single-arm, open-label, phase II study of Eutidrone versus Cisplatin/Carboplatin combined with Envafolimab in patients with advanced non-small cell lung cancer

Recruiting
4
51
 
Eutidrone versus Cisplatin/Carboplatin combined with Envafolimab
The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Cancer Hospital); The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Cancer Hospital), Self-raised
NSCLC
 
 
ChiCTR2500100348: Neoadjuvant Envafolimab plus Chemotherapy in Locally Advanced Head and Neck Carcinoma: an open-label clinical trial

Recruiting
4
38
 
Neoadjuvant Envafolimab plus Chemotherapy
Peking University Hospital of Stomatology; Peking University Hospital of Stomatology, Self raised funds
squamous cell carcinoma of the head and neck
 
 
KN035-BTC, NCT03478488: Programmed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTC

Active, not recruiting
3
480
RoW
KN035 plus Gemcitabine & oxaliplatin, Experimental, Gemcitabine & oxaliplatin, Active Comparator
3D Medicines (Sichuan) Co., Ltd.
Biliary Tract Neoplasms
09/24
12/26
PRECAM-R, NCT05752136: Preoperative Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Rectal Adenocarcinoma

Recruiting
3
108
RoW
Envafolimab
Sir Run Run Shaw Hospital
Rectal Cancer
04/25
12/28
KN035-CN-017, NCT06123754: Phase III Study of Envafolimab Versus Placebo Plus Chemotherapy in Resectable Stage III NSCLC

Recruiting
3
390
RoW
Envalfolimab subcutaneously injected+Platinum-based doublet chemotherapy intravenous injection, Experimental, placebo subcutaneously injected +Platinum-based doublet chemotherapy intravenous injection, Active Comparator
3D Medicines (Sichuan) Co., Ltd.
Non-small Cell Lung Cancer
12/25
09/27
NCT06959693: A Clinical Study to Evaluate the Efficacy and Safety of Envafolimab Combined With Cetuxima-βand mFOLFOX6 in Patients With MSS, RAS/BRAF Wild-Type Metastatic Colorectal Cancer (mCRC)

Not yet recruiting
2/3
590
RoW
Cetuxima-β, Envafolimab, mFOLFOX6
Sun Yat-sen University
Metastatic Colorectal Cancer (CRC)
09/28
06/30
ChiCTR1800017857: KN035 prospective single arm phase II clinical study on efficacy and safety in the treatment of patients with advanced multiple primary tumors

Not yet recruiting
2
20
 
KN035
Renji Hospital Affiliated to Medical School of Shanghai Jiaotong University; Renji Hospital, Shanghai shenkang hospital development center clinical science and technology innovation project - municipal hospital clinical research and cultivation project
Multiple primary tumors
 
 
CISLD-12, NCT05213221: Study on Therapeutic Effect of Combination of Envafolimab, Lenavatinib and TACE in Advanced HCC Patients

Completed
2
39
RoW
Envafolimab, TACE, Lenvatinib
Zhejiang University
Advanced Hepatocellular Carcinoma
09/22
06/23
NCT05298020: Envafolimab Combined With Endostar and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer

Not yet recruiting
2
20
RoW
Envafolimab, Immunotherapy, Endostar, endostatin, Nab paclitaxel, Chemotherapy, Gemcitabine
The Affiliated Hospital of Xuzhou Medical University
Advanced Pancreatic Cancer
12/22
04/23
ENLEN-OC-001, NCT05422183: Envafolimab, Lenvatinib Combined With VP-16 in Platinum-resistant Recurrent Epithelial Ovarian Cancer

Not yet recruiting
2
20
RoW
Envafolimab, Immunotherapy, Lenvatinib, Tyrosine kinase inhibitors, VP-16, Chemotherapy
Zhongda Hospital
Ovarian Cancer, Epithelial
12/22
12/23
NCT05237349: Envafolimab Combined With Chemotherapy in Metastatic or Recurrent Gastric Adenocarcinoma

Recruiting
2
38
RoW
Envafolimab, Immunotherapy, Oxaliplatin, Chemotherapy, S1
Liangjun Zhu M.M., Zhangjiagang First People's Hospital
Metastatic or Recurrent Gastric Adenocarcinoma
12/24
12/24
PRECAM, NCT05216653: Preoperative Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Rectal Adenocarcinoma

Completed
2
32
RoW
Envafolimab, KN053, Oxaliplatin, Capecitabine, Short-course Radiation, TME surgery, total mesorectal excision
Sir Run Run Shaw Hospital
MSS Locally Advanced Rectal Adenocarcinoma
03/23
03/25
SLKYLX2023-006, NCT06239870: Single-arm, Single-center, Exploratory Phase II Clinical Study of Envafolimab Combined With Chemoradiotherapy in the Treatment of Locally Advanced pMMR/MSS Rectal Cancer

Recruiting
2
35
RoW
Envafolimab combined with chemoradiotherapy in the whole course of neoadjuvant therapy
Yunnan Cancer Hospital, Beijing Bethune Charitable Foundation
Envafolimab Combined With Chemoradiotherapy in the Treatment of Locally Advanced pMMR/MSS Rectal Cancer
09/25
09/25
NCT05335460: To Determine the Efficacy and Safety of Envafolimab Combined With XELOX for Locally Advanced Colon Cancer

Not yet recruiting
2
36
NA
Envafolimab, XELOX( Oxaliplatin 130mg/m2,ivgtt, Q3w capecitabine 1000mg/m2, p.o Q3w)
Fujian Cancer Hospital
Colon Cancer
05/23
05/24
NSCLC-LXL002, NCT05360979: A Clinical Study of Immunotherapy Combined With Chemotherapy and Anti-angiogenic Therapy in Operable NSCLC

Enrolling by invitation
2
42
RoW
envafolimab, recombinant human endostatin, chemotherapy
Second Xiangya Hospital of Central South University
Non-small Cell Lung Cancer
05/23
05/25
NCT05551247: Envafolimab Combined With Endostatin in Recurrent or Metastatic MSS-type Colorectal Cancer

Not yet recruiting
2
30
NA
Envafolimab, recombinant human endostatin (endostatin)
First Affiliated Hospital Xi'an Jiaotong University
Colorectal Neoplasms
06/23
06/24
ChiCTR1900021607: A Phase II, Single-arm and Open-labelled Clinical Study of Anti-PD-L1 Antibody KN035 Combined with Trastuzumab and Docetaxel in the Treatment of HER2-positive Advanced Breast Cancer

Recruiting
2
59
 
Conventional chemotherapy (TH regimen) combined with KN035 5mg/kg/3w
Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Natural Science Foundation of China (81622036)
breast cancer
 
 
ASC-ASC22-II-CTP-01, NCT04465890: A Phase II Study of Subcutaneously Injected PD-L1 Antibody ASC22 in Chronic Hepatitis B Patients

Completed
2
207
RoW
ASC22, sodium chloride
Ascletis Pharmaceuticals Co., Ltd., Peking University First Hospital, Beijing Clinical Service Center
Chronic Hepatitis b
08/24
08/24
NCT05148195: A Phase II Study of Envofolimab and BD0801 With/Without Chemotherapy in Patients With Advanced Solid Tumors

Terminated
2
86
RoW
Envofolimab, BD0801, Docetaxel, Irinotecan, Leucovorin calcium, 5-Fluorouridine
Jiangsu Simcere Pharmaceutical Co., Ltd.
Advanced Solid Tumor
07/23
07/23
NCT05387681: Preoperative Short Course Radiotherapy With Envafolimab, Endostatin and SOX Regimen in Locally Advanced Gastric

Not yet recruiting
2
35
NA
Envafolimab, Endostatin
Wuhan Union Hospital, China
Gastric/Gastroesophageal Junction Adenocarcinoma, Radiotherapy, Immunotherapy
07/23
12/25
NCT05529355: Effect and Safety of Envafolimab Combined With Endostar/S-1 in Second-line of Advanced Non-small Cell Lung Cancer

Not yet recruiting
2
45
NA
Envafolimab plus Endostar and S-1, Envafolimab combined with Recombinant Human Endostatin Injection/Tegafur,Gimeracil and Oteracil Porassium Capsules, Envafolimab plus Endostar, Envafolimab combined with Recombinant Human Endostatin Injection, Envafolimab plus S-1, Envafolimab combined with Tegafur,Gimeracil and Oteracil Porassium Capsules
Anhui Chest Hospital
Carcinoma, Non-Small-Cell Lung
09/23
09/23
NCT05582109: Envafolimab, Lenvatinib Combined With TACE in the Treatment of Unresectable Locally Advanced Hepatocellular Carcinoma

Not yet recruiting
2
30
NA
Envafolimab, Lenvatinib Combined With TACE
Tianjin Medical University Cancer Institute and Hospital
Objective Response Rate (ORR)
10/23
10/25
NCT05068427: Trial of Chidamide in Combination With Envafolimab in Patients With PD-1 Inhibitor Resistant Advanced NSCLC.

Completed
2
34
RoW
Chidamide, CS055, Envafolimab, KN035
Chipscreen Biosciences, Ltd.
Non Small Cell Lung Cancer
02/23
05/24
NCT05243355: Envafolimab Combined With Chemotherapy and Recombinant Human Endostatin in the First-line Treatment of Sq-NSCLC

Recruiting
2
46
RoW
"Envafolimab" and "Chemotherapy" and "Recombinant Human Endostatin"
Qilu Hospital of Shandong University
Squamous Non-small Cell Lung Cancer
12/23
12/24
NCT05330143: Study to Evaluate Safety, Tolerance and Efficacy of ASC22 Combined With ART in Subjects With HIV

Completed
2
19
RoW
ASC22 1mg/kg, KN035, ASC22 2.5mg/kg, Antiretroviral Therapy, Placebo
Ascletis Pharmaceuticals Co., Ltd.
HIV-1-infection, HIV Infections, PD-L1 Gene Mutation
05/24
05/24
NCT06143579: A Study of HAIC Combined With Lenvatinib and Envolizumab in Potentially Resectable Hepatocellular Carcinoma

Not yet recruiting
2
48
NA
FOLFOX-HAIC+Lenvatinib+Envolizumab, KN035
Sun Yat-sen University
Potentially Resectable Hepatocellular Carcinoma
03/25
12/26
NCT05552651: Envafolimab Combined With Chemotherapy in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma

Not yet recruiting
2
40
NA
Envafolimab, Albumin-Bound Paclitaxel, Carboplatin
Tao Jiang
Esophageal Squamous Cell Carcinoma
12/23
12/23
NCT03667170: KN035 for dMMR/MSI-H Advanced Solid Tumors

Recruiting
2
200
RoW
KN035
3D Medicines (Sichuan) Co., Ltd.
Solid Tumor
12/25
12/26
NCT05112991: Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer

Recruiting
2
108
RoW
Envafolimab+Lenvatinib, Envafolimab
3D Medicines (Sichuan) Co., Ltd.
Advanced Endometrial Cancer
12/25
12/25
ESTIMATE, ChiCTR2400079718: Single-arm, single-center, exploratory Phase II clinical study of Envafolimab combined with chemoradiotherapy in the treatment of locally advanced pMMR/MSS rectal cancer

Recruiting
2
35
China
Enweida (envafolimab) - 3DMed, Tracon Pharma, Ascletis, capecitabine - Generic mfg.
Yunnan Cancer Hospital, Beijing Bethune Charitable Foundation
pMMR/MSS locally advanced rectal cancer
 
 
NCT06218004: Envafolimab Combined With Chemotherapy in Neoadjuvant and Conversion Therapy for Head and Neck Squamous Cell Carcinoma

Not yet recruiting
2
40
NA
Envafolimab combined with chemotherapy, Envafolimab
Hairong Liu
Efficacy and Safety
12/25
12/25
 

Download Options